Any significant medical complications related to therapy must have resolved All associated clinically significant toxicity from previous cancer therapy must be resolved (to ?Grade or baseline) prior to study treatment administration (Grade alopecia is allowed). Has an EGFR TKI- related toxicity that has NOT resolved to Grade or less. All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< prior to study entry Toxicity from prior therapy (except alopecia) has resolved to ?Grade ; in the event of toxicity that has not resolved to ?Grade but is considered stable, the patient may be eligible after discussion among the investigator and sponsor's medical monitor. Persistent toxicity from recent therapy that has not sufficiently resolved in the judgment of the study physician. Prior treatment-related toxicity resolved to =< grade or baseline Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade = grade treatment-related toxicity from previous chemotherapy should be resolved Grade >= nonhematological toxicity from prior therapy that has not resolved to =< grade Presence of an acute or chronic toxicity of prior chemotherapy that has not resolved to ? Grade , as determined by CTCAE v .. Toxicity from previous treatment including: a) Toxicity Grade >= related to prior immunotherapy and that lead to study treatment discontinuation. b) Toxicity related to prior treatment has not resolved to Grade <= (except alopecia, or endocrinopathy managed with replacement therapy). All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< Any significant medical complications related to consolidation cycle must have resolved Any toxicity related to prior EGFR inhibitor treatment must have resolved to Grade \n or less Grade or immune related toxicity associated with prior ipilimumab therapy that has not resolved to grade or All acute treatment-related toxicity must have resolved to Grade less than or equal to (= grade neurotoxicity or any other toxicity requiring discontinuation of taxane therapy that has not resolved to =< grade , with the exception of alopecia Toxicity from prior therapy (excluding alopecia) that has not resolved to =< grade prior to the first treatment with G- Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< except neuropathy Toxicity from prior radiation therapy has NOT resolved to grade or less All toxicity related to prior cancer therapies must have resolved to ? Grade , with the following exceptions: alopecia; neuropathy, which must have to resolved to ? Grade ; and congestive heart failure (CHF), which must have been ? Grade in severity and must have resolved completely. Any toxicity related to prior cancer therapies that has not resolved to =< grade , with the exception of peripheral neuropathy, which must have resolved to =< grade , and alopecia Toxicity from prior chemotherapy that has not resolved to Grade ? ; All associated toxicity from previous or concurrent cancer therapy must be resolved (to ?Grade or Baseline) prior to study treatment administration All associated toxicity from previous or concurrent cancer therapy must be resolved (to ? Grade or Baseline) prior to study treatment administration. All associated toxicity from previous or concurrent cancer therapy must be resolved (to ? Grade or Baseline) prior to study treatment administration. All acute treatment-related toxicity from prior therapy must have resolved to Grade ? prior to study entry Acute prior study treatment related toxicity (except alopecia) that has not resolved to Grade < or = to unless it has been deemed stable by the investigator All acute treatment-related toxicity from prior therapy must have resolved to Grade ? prior to study entry All acute treatment-related toxicity from prior therapy must have resolved to Grade ? prior to study entry All acute treatmentrelated toxicity from prior therapy must have resolved to Grade ? prior to study entry The patient has a prior ALK-inhibitor-related toxicity or any other prior therapy-related acute toxicity that has not resolved prior to the first dose of study drug. Residual > Grade toxicity from prior treatment must have resolved with the exception of those explicitly described elsewhere in entry criteria Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia, that has not resolved to Grade ? within days prior to start of CA- unless approved by the Medical Monitor Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ? (according to the NCI CTCAE, v.) prior to Cycle Day All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< Any grade or clinically significant grade treatment-related non-hematological toxicity must be resolved to grade before retreatment with chemotherapy (with exception of alopecia) Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade less than or equal to ( days prior to initiation of study treatment. In addition, clinically significant toxicities associated with any prior therapy for the primary cancer, including investigational treatments, have resolved or stabilized to Grade ? toxicity > days prior to initiation of study treatment with the exception of neuropathy, which must have resolved to Grade ?. Continuation of a stable dose (minimum of days prior to study entry) of denosumab or bisphosphonate is permitted on study.